




Searching News Database: CRISPR/Cas
HSMN NewsFeed - 3 Aug 2023
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
HSMN NewsFeed - 26 Jan 2022
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
HSMN NewsFeed - 8 Aug 2019
Bayer Acquires Bluerock Therapeutics to Build Leading Position in Cell Therapy
Bayer Acquires Bluerock Therapeutics to Build Leading Position in Cell Therapy
HSMN NewsFeed - 24 Jan 2019
Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
HSMN NewsFeed - 2 Apr 2018
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
HSMN NewsFeed - 20 Feb 2017
DiaCarta Receives CE-IVD for its Non-Invasive Colorectal Cancer Test - ColoScape(TM) Real-Time PCR Kit
DiaCarta Receives CE-IVD for its Non-Invasive Colorectal Cancer Test - ColoScape(TM) Real-Time PCR Kit
HSMN NewsFeed - 8 Dec 2016
Agenovir Appoints Industry Veteran Dirk Thye, M.D. As Chief Executive Officer
Agenovir Appoints Industry Veteran Dirk Thye, M.D. As Chief Executive Officer